Interview with Peter van Tilburg, General Director / President, Cambridge Major…
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Address: Cambridge Major Laboratories Europe, B.V., Peelterbaan 2, 6002 NK Weert, Industrial area “De Kempen”, the Netherlands
Tel: ++31 (0)495 549 072
Web: http://www.c-mlabs.com/faceu.html
Cambridge Major Laboratories provides advanced chemistry services to the worlds leading pharmaceutical and biotechnology companies. We boast an impeccable reputation for delivering some of the most challenging projects and meeting the tightest timelines. And Cambridge Major’s reach is truly global in nature, operating four facilities in the US and Europe, serving hundreds of companies across the world.
Our philosophy revolves around strong R&D. With almost 50% of our scientists holding a Ph.D., Cambridge Major is well positioned to deliver on the most challenging and complex chemistry projects. Strong R&D to support early scale up during pre-clinical development will ensure that your molecule will transition into first-in-human studies as smoothly as possible. And we have the resources to provide all of your clinical and commercial API needs.
So when you are looking for a trusted partner to help take your molecule from concept to clinic and beyond, look to Cambridge Major. WE DELIVER.
The Weert facility (formerly ChemShop BV) is a 12,500 square meter site specializing in medicinal chemistry, process development, scale-up, clinical supplies, and low volume commercial supply of API’s. The facility houses fully isolated pilot suites with reactors of up to 1000 liter, and is fully GMP and ISO14001 certified. The facility has a wide range of capabilities including plant scale cryogenics (-100C) and high temperature (300C), high pressure reactions and high vacuum distillations.
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Kees Smaling, Managing Director of Siemens Healthcare, which recently completed its first Dutch (and European) hospital financing, explains the strategic thinking that sustains Siemens’ shift to become a more comprehensive…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
Floris Van Haselen, Business Development Director Europe for O&M Movianto, one of the rare logistics companies to be fully specialized and to only operate in the healthcare sector, explains how the company…
Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares…
Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has…
Rob de Roock, Director CL Healthcare for UPS Europe, gives us a brief outline of the current market dynamics impacting the booming European healthcare logistics industry and explains how UPS…
Han Brouwer, General Manager for Actelion in the Netherlands, explains how Opsumit’s successful market launch has strengthened Actelion’s leadership position in the pulmonary arterial hypertension (PAH) field. He calls for…
Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager…
Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D…
See our Cookie Privacy Policy Here
